In this interview with In Vivo, Theolytics CEO Charlotte Casebourne talks to In Vivo about the challenge of standing out from the crowd in oncology, how viruses have evolved as a treatment approach in cancer, and how oncolytic viruses might be the answer to the cancer drug pricing conundrum. As the oncolytic virus company gears up to raise a series A round and get its preclinical assets into human trials by 2021, learn what this rising CEO has to say about the dramatic changes in the R&D sector in recent years, what excites her in the oncology space in terms of development trends and innovation, and the biggest challenges she sees in cancer drug development today.